![Tassos Gianakakos](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tassos Gianakakos
Keine laufenden Positionen mehr
Vermögen: 198 Mio $ am 31.08.2026
Profil
Derzeit hat Anastasios E. Gianakakos die Position des Chief Executive Officer bei MyoKardia, Inc. inne. Er ist auch im Vorstand von LianBio. In der Vergangenheit war Anastasios E. Gianakakos President & Senior VP-Business Development bei Codexis, Inc. und Prozessingenieur bei Merck & Co, Inc. sowie Director -Business Development bei Maxygen, Inc. und Chief Business Officer & Senior Vice President bei MAP Pharmaceuticals LLC. Er erhielt einen Undergraduate-Abschluss vom Massachusetts Institute of Technology, einen Graduate-Abschluss von der Northwestern University und einen MBA von der Harvard Business School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
10,49 % | 30.06.2026 | 9.806.633 ( 10,49 % ) | 198 Mio $ | 31.08.2026 |
LIANBIO 0,35 % | 15.02.2024 | 363.253 ( 0,35 % ) | 18 072 $ | 31.08.2026 |
Aktive Positionen von Tassos Gianakakos
| Unternehmen | Position | Beginn |
|---|
Ehemalige bekannte Positionen von Tassos Gianakakos
| Unternehmen | Position | Ende |
|---|---|---|
Prolaio, Inc.
 Prolaio, Inc. BiotechnologyHealth Technology Operates as a patient-centered clinical intelligence company dedicated to cardiology research and care ecosystem | Vorstandsvorsitzender | 01.02.2025 |
| LIANMEDICAL | Direktor/Vorstandsmitglied | 01.03.2024 |
| MYOKARDIA, INC. | Vorstandsvorsitzender | 01.11.2020 |
MAP Pharmaceuticals LLC
 MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology Develops therapies and inhalation delivery technologies | Corporate Officer/Principal | 01.03.2013 |
| MERCK & CO., INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1997 |
Ausbildung von Tassos Gianakakos
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
64
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Develops directed molecular evolution technology | Commercial Services |
Codexis, Inc.
 Codexis, Inc. Chemicals: SpecialtyProcess Industries Develops biocatalytic chemical processes | Process Industries |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology Develops therapies and inhalation delivery technologies | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of cardiovascular diseases | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LianBio
 LianBio BiotechnologyHealth Technology Operates as a biotechnology company focused on bringing paradigm-shifting medicines to patients | Health Technology |
Prolaio, Inc.
Prolaio, Inc. BiotechnologyHealth Technology Operates as a patient-centered clinical intelligence company dedicated to cardiology research and care ecosystem | Health Technology |
